Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
about
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisUpdated national and international hypertension guidelines: a review of current recommendationsSystematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleedingThe effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trialsALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesPropensity score methods for confounding control in nonexperimental researchDiscovery and Development of Calcium Channel Blockers.A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.African Americans, hypertension and the renin angiotensin systemStroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda.Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response PhenotypesTrends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension.Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHATConcepts guiding therapy for hypertension in children.Type 2 diabetes mellitus and hypertension: an update.Improving blood pressure control rates by optimizing combination antihypertensive therapy.How early should blood pressure control be achieved for optimal cardiovascular outcomes?Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association.Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.Role of dihydropyridinic calcium channel blockers in the management of hypertension.Calcium channel blockers in cardiovascular pharmacotherapy.Salt, Angiotensin II, Superoxide, and Endothelial Function.The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis.Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis.GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence.Association of worsening arterial stiffness with incident heart failure in asymptomatic patients with cardiovascular risk factors.Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring - utility of "hypobaric curve" and "hypobaric area".Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: a meta-analysis of randomized controlled trials.A 59-year-old man with racial characteristics.Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients.Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.The treatment of hypertension in the elderly.Patient characteristics do not predict the individual response to antihypertensive medication: a cross-over trial.
P2860
Q24186647-500CE7BF-E9DC-4678-B05E-B87A54ED30BDQ24194514-D99CA4C4-E25B-4556-AEEC-6992D671E9D3Q26824589-CE731352-1CF2-4C39-99ED-649BF8CAE3A6Q28081521-F70F8B44-EF7A-4C78-9213-D8D3F678E239Q28487721-8C2D52F3-F20A-4BB0-9813-9248F9504ED6Q33576830-BDEA2FC9-7E01-4D3D-8724-CFEAE7632E33Q33654170-070AFA6F-148A-4704-A650-E12CA5F053DEQ33734936-838937FF-A9B4-4795-A44B-F45B3BE6E342Q34018990-5832D727-BF4B-4747-973B-765181D0A4E2Q34226785-1C4DF4BC-9BD4-460A-9478-DFAA6175CC3CQ34251854-97A03A65-BE7B-46B3-B734-54B015346213Q34625364-4BE68577-929B-424C-A34E-F4D16038778EQ35210587-45739770-75FE-4B79-8717-FF5163BFB560Q36195598-A40FE7C0-2C63-4FAA-A8ED-CF4A7983932BQ36473120-34603964-F7EE-4DA8-A7EA-EE6EA373E12EQ37098424-DD18C8FA-DFBF-406D-B64C-DD7F6EBC0954Q37199928-AE8AD946-B1D7-4ABA-9182-2BED47D19294Q37352660-94A18F37-D45D-4F48-AD3A-3BA0CB0224DBQ37510996-CF57D24B-1713-4663-869E-5CB554B04765Q37617567-67C7E585-8EFA-473F-88F2-33F74C9FD8CFQ37768793-2CB70B93-C4EC-4FB3-B8D3-517FFC48E1B0Q37769409-B30CA411-4677-4968-B325-6EC0004DA2C3Q37810914-F7B13C5E-46A7-4098-AE60-F9090D06A7CFQ37828060-430245EA-9CD0-4E5A-B928-8AB34CA60BEBQ37956404-8DC2ACCF-6FE3-478F-AC10-0B29CBBC1325Q38069195-B6E256E2-C7C4-4456-8EF4-0A0BBD863EF2Q38215726-ACD8D938-9E73-4E2E-8730-7740F9CDC733Q38693277-0C346483-23A2-4AA5-A55E-79775AFF5220Q38751502-4DA59DD1-28D6-45F2-AC22-A1E4E46874A8Q38780214-1B134D91-C8E6-4FB0-8014-5162305FD2DCQ39227527-44383A1F-8928-4F92-944B-A254D5E9DD21Q40599528-15523E4C-0458-4A15-90EA-21F984E97D2BQ44606462-9BAAED39-B76D-49A5-B03D-3C98D3ED78C9Q45340581-05B6FBC2-5841-4F3D-8939-96D8B4BDC416Q46476369-B28E8316-ABB2-42C4-A060-6C821DE9D0F5Q46562954-81BCE27C-8FDF-456A-8CF1-AB1ABAABA14FQ46713618-E33037EA-852A-430C-9F25-31D0D3F40A11Q46842382-2804C5CB-A30A-4321-9D0F-8D1783D9F458Q46902957-19494CA3-BE0A-4A80-9A41-0097EE120625Q47623007-3438AC19-0FDD-455E-85DC-693CF53BA107
P2860
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical events in high-risk h ...... to prevent heart attack trial.
@ast
Clinical events in high-risk h ...... to prevent heart attack trial.
@en
Clinical events in high-risk h ...... to prevent heart attack trial.
@nl
type
label
Clinical events in high-risk h ...... to prevent heart attack trial.
@ast
Clinical events in high-risk h ...... to prevent heart attack trial.
@en
Clinical events in high-risk h ...... to prevent heart attack trial.
@nl
prefLabel
Clinical events in high-risk h ...... to prevent heart attack trial.
@ast
Clinical events in high-risk h ...... to prevent heart attack trial.
@en
Clinical events in high-risk h ...... to prevent heart attack trial.
@nl
P2093
P1433
P1476
Clinical events in high-risk h ...... to prevent heart attack trial.
@en
P2093
Aloysius B Cuyjet
Antihypertensive and Lipid-Low ...... l Collaborative Research Group
Barry R Davis
Chuke E Nwachuku
Frans H H Leenen
Henry R Black
Jackson T Wright
James V Felicetta
Jan N Basile
L Julian Haywood
P304
P356
10.1161/01.HYP.0000231662.77359.DE
P407
P577
2006-07-24T00:00:00Z